Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.14 -0.17%

-$0.01 today

Market cap
$277.81M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.82M

Average 0.82M

Returns on capital

Agenus Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-0.0%

avg 100.1%

ROIC

-34.5%

avg -169.1%

ROA

0.1%

avg -64.7%

Analysis

ROA is currently the strongest return metric at 0.1% versus its period average of -64.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Garo H. Armen

Founder, Interim CFO, Principal Financial Officer, CEO & Executive ChairmanUSD 1.21M731.97M4.73%

Steven J. O'Day

Chief Medical OfficerUSD 902.82K65100.00K0.24%

Craig Winter

Chief Information Officer————

Kamel Djazouli

Head of Medical Affairs————

Zack Armen

Vice President of Investor Relations & Corporate Development————

Stefanie Perna-Nacar

Chief Communications & Government Relations Officer————

Tracy Mazza Clemente

Chief People Officer————

Robin G. Taylor

Chief Commercial Officer————

Todd Jude Yancey

Member of Advisory Board & Chief Strategic Advisor————

Jennifer S. Buell

Director and President & Chief Executive Officer of MiNK Therapeutics—51——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+5.2%
+4.4% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +5.2% over three years. Forward estimates point to Revenue at +4.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Agenus Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AGEN's management, answered from reported figures.

Who manages AGEN?

Agenus Inc. (AGEN) lists 10 active executives. The top listed executive is Craig Winter, Chief Information Officer.

Are AGEN insiders buying or selling?

Recent insider activity shows net buying of $37.96M.